Evidence map›Paper›PMID 42292172›Full record

ArticleFrontiers in medicine2026

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report.

Qiu Ming He, Jun Jie Tang, Chao Hao, Yi Jiang, Ji Huang, Jian Biao Huang, Xin Hua Tu

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiu Ming He *Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Jun Jie Tang *Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Chao HaoJiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Yi JiangJiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Ji HuangJiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Jian Biao HuangJiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Xin Hua TuJiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article reports the diagnosis and treatment of an 81-year-old man with advanced prostate cancer presenting with multiple organ metastases. The patient had undergone laparoscopic radical prostatectomy 5 years prior and received intermittent postoperative endocrine therapy with leuprorelin acetate and bicalutamide. He presented with hematuria, and laboratory evaluation revealed a markedly elevated prostate-specific antigen level (total PSA 274.71 ng/mL, free PSA 63.50 ng/mL). Contrast-enhanced CT demonstrated bilateral renal masses, retroperitoneal lymphadenopathy, and liver metastases. A biopsy of the right renal lesion confirmed metastatic prostate acinar adenocarcinoma, with immunohistochemistry showing PSA (+), Ki67 (40%, indicating high proliferative activity), and succinate dehydrogenase subunit B (SDHB) (+). Following a change in the endocrine therapy regimen to rezvilutamide combined with degarelix, the patient's hematuria significantly improved. This case highlights the critical importance of rigorous postoperative surveillance and timely, standardized endocrine therapy in prostate cancer management. It also contributes to the limited literature on visceral metastases in castration-sensitive prostate cancer (HSPC) and underscores the need for further exploration of optimal treatment strategies for advanced metastatic disease.

Indexed as

endocrine therapyhepatic metastasismonitoringprostate cancerrenal metastasis

Identifiers

PMID42292172
PMCPMC13259896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.